These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4972210)

  • 21. [The morphologic composition of peripheral blood following intra-arterial infusion of 5-fluorouracil and alkylating preparations in stomach cancer patients].
    Chernyĭ VA
    Vopr Onkol; 1970 Apr; 16(4):61-4. PubMed ID: 4989339
    [No Abstract]   [Full Text] [Related]  

  • 22. [Spontaneously cured pancytopenia due to intravesical thio-tepa, apropos of one case].
    Archimbaud JP; Calcat P; Martel JP
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):487-8. PubMed ID: 4216648
    [No Abstract]   [Full Text] [Related]  

  • 23. [A patient with ovarian cancer metastasis cured (?) by cytostatic agents and died from acute myeloid leukemia].
    Sypkens Smit CG; Meyler L
    Ned Tijdschr Geneeskd; 1970 Sep; 114(39):1620-3. PubMed ID: 4990178
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cytostatic treatment of lymphogranulomatosis. Experiences with ibenzmethyzine, cyclophosphamide and vinblastine sulfate].
    Schubert JC; Martin H
    Munch Med Wochenschr; 1968 Jan; 110(2):97-100. PubMed ID: 5695132
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of disseminated breast cancer with triethylen-thiophosphoramide (thio-tepa)].
    Madrigal Alonso PL; Perez Gomez FJ
    Acta Oncol (Madr); 1969; 8(2):135-42. PubMed ID: 4988905
    [No Abstract]   [Full Text] [Related]  

  • 26. [Chemotherapy in the combined treatment of malignant ovarian tumors].
    Sirota IG
    Pediatr Akus Ginekol; 1967; 4():55-7. PubMed ID: 4983870
    [No Abstract]   [Full Text] [Related]  

  • 27. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
    Dzhilavian GA; Vinokurov VL
    Vopr Onkol; 1984; 30(3):16-21. PubMed ID: 6424327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intratumor chemotherapy of patients with cancer of the ovaries].
    Vinokurov VL; Mitrokhina MV
    Vopr Onkol; 1983; 29(8):58-61. PubMed ID: 6310891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experiences in the treatment of leukopenia due to cytostatic therapy of ovarian and breast neoplasms].
    Limburg H; Müller K; Brachetti AK
    Med Welt; 1977 Aug; 28(32-33):1304-7. PubMed ID: 562966
    [No Abstract]   [Full Text] [Related]  

  • 33. Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
    Cass I; Kuo DY; Fields AL; Runowicz CD; Goldberg GL
    Gynecol Oncol; 1998 May; 69(2):175-8. PubMed ID: 9600828
    [No Abstract]   [Full Text] [Related]  

  • 34. Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer.
    Shapiro CL; Dezube BJ; Tretyakov O; Wright J; Cap B; Henderson IC; Hayes DF
    Clin Cancer Res; 1995 Aug; 1(8):791-6. PubMed ID: 9816047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer.
    Mangioni C; Bolis G; Natale N; Morasca L
    Eur J Cancer (1965); 1976 May; 12(5):353-6. PubMed ID: 954793
    [No Abstract]   [Full Text] [Related]  

  • 36. Thiotepa-induced myelosuppression: review of 670 bladder instillations.
    Soloway MS; Ford KS
    J Urol; 1983 Nov; 130(5):889-91. PubMed ID: 6415297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Usual harmlessness of endovesical instillations of thio-tepa].
    des Roseaux M; Vacant J; Beurton D; Cukier J
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):485-7. PubMed ID: 4216647
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide.
    Beck RE; Boyes DA
    Can Med Assoc J; 1968 Mar; 98(11):539-41. PubMed ID: 5647240
    [No Abstract]   [Full Text] [Related]  

  • 39. [Breast cancer].
    Wobbes T
    Ned Tijdschr Tandheelkd; 1992 Jan; 99(1):9-11. PubMed ID: 11819994
    [No Abstract]   [Full Text] [Related]  

  • 40. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
    van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
    Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.